CYTK
Cytokinetics, Incorporated
Stock
$65.62−0.29 (−0.44%)Close Oct 1, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$555M | −$510M | −$396M | −$414M | −$300M | −$143M | $8.9M | −$91M | −$101M | −$102M | $37M | $4.9M | −$45M | −$7.7M | −$33M | −$46M | −$45M | $8.4M |
| Capital expenditures | $25M | $25M | $3.9M | $1.4M | $11M | $49M | $11M | $2.6M | $889K | $2.9M | $1.6M | $562K | $1.1M | $542K | $125K | $443K | $493K | $550K |
| Free cash flow | −$581M | −$535M | −$400M | −$416M | −$311M | −$191M | −$2.1M | −$94M | −$102M | −$105M | $35M | $4.3M | −$46M | −$8.3M | −$34M | −$46M | −$45M | $7.9M |
| Stock-based compensation | $127M | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $9.8M | $9.0M | $7.1M | $4.6M | $3.3M | $3.6M | $3.8M | $3.1M | $4.0M | $4.9M |
| Free cash flow margin | −858.2% | −607.5% | −2,164.1% | −5,521.2% | −328.6% | −271.8% | −3.8% | −348.1% | −324.1% | −782.7% | 33.3% | 15.1% | −97.9% | −27.0% | −444.0% | −1,150.9% | −1,758.8% | 9.6% |